Gross Unrealized Gains
Regeneron Pharmaceuticals Gross Unrealized Gains decreased by 58.5% to $40.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 28.2%, from $57.00M to $40.90M. Over 5 years (FY 2020 to FY 2025), Gross Unrealized Gains shows an upward trend with a 19.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher unrealized gains generally indicate a favorable interest rate environment or strong performance of the underlying assets.
Detailed definition
This metric tracks the total gross unrealized gains on debt securities classified as available-for-sale. It represents t...
Peer comparison
This metric is highly sensitive to market interest rates and is a standard disclosure for all banks with large investment portfolios.
other_available_for_sale_debt_securities_accumulated_gro_8d5dbcHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $25.80M | $21.00M | $10.80M | $1.30M | $100.00K | $100.00K | $900.00K | $10.60M | $1.50M | $900.00K | $13.70M | $7.00M | $4.10M | $100.80M | $30.10M | $57.00M | $77.70M | $93.20M | $98.50M | $40.90M |
| QoQ Change | — | -18.6% | -48.6% | -88.0% | -92.3% | +0.0% | +800.0% | >999% | -85.8% | -40.0% | >999% | -48.9% | -41.4% | >999% | -70.1% | +89.4% | +36.3% | +19.9% | +5.7% | -58.5% |
| YoY Change | — | — | — | — | -99.6% | -99.5% | -91.7% | +715.4% | >999% | +800.0% | >999% | -34.0% | +173.3% | >999% | +119.7% | +714.3% | >999% | -7.5% | +227.2% | -28.2% |
Gross Unrealized Gains at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's gross unrealized gains?
- Regeneron Pharmaceuticals (REGN) reported gross unrealized gains of $40.90M in Q1 2026.
- How has Regeneron Pharmaceuticals's gross unrealized gains changed year-over-year?
- Regeneron Pharmaceuticals's gross unrealized gains decreased by 28.2% year-over-year, from $57.00M to $40.90M.
- What is the long-term trend for Regeneron Pharmaceuticals's gross unrealized gains?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's gross unrealized gains has grown at a 19.7% compound annual growth rate (CAGR), from $40.10M to $98.50M.
- What does gross unrealized gains mean?
- The total amount of unrealized gains on debt securities that are held for potential sale.